Biohit Oyj - Total number of voting rights and capital

NOTIFICATION OF A CHANGE IN BIOHIT OYJ SHARE OWNERSHIP IN ACCORDANCE WITH THE SECURITIES MARKETS ACT, CHAPTER 2, SECTION 10

BIOHIT OYJ STOCK EXCHANGE RELEASE, 24 JUNE 2009 at 3:30 PM                      

NOTIFICATION OF A CHANGE IN BIOHIT OYJ SHARE OWNERSHIP IN ACCORDANCE WITH THE   
SECURITIES MARKETS ACT, CHAPTER 2, SECTION 10                                   

In accordance with the Securities Markets Act, Chapter 2, Section 9, Biohit Oyj 
today received notification that the combined share of voting rights conferred  
by shares owned by Professor Pentti Sipponen and Patolab Oy - a company in his  
control - has fallen to under one twentieth.                                    

In a transaction made on 24 June 2009, ownership of a total of 900,000 Series B 
shares held by Pentti Sipponen was transferred to Biocosmos Oy (450,000 shares) 
and Interlab Oy (450,000 shares) - two companies under the control of Professor 
Osmo Suovaniemi.                                                                

In accordance with the Securities Markets Act, Chapter 2, Section 10, Biohit Oyj
is issuing notification that, as a result of the above transaction, the         
percentage of shares and votes held by Pentti Sipponen and any companies in his 
control are as follows:                                                         

--------------------------------------------------------------------------------
|                           |       Number of |     % of shares |   % of votes |
|                           |          shares |                 |              |
--------------------------------------------------------------------------------
| Pentti Sipponen           |                 |                 |              |
--------------------------------------------------------------------------------
|   Series B shares         |               0 |            0.00 |         0.00 |
--------------------------------------------------------------------------------
| Patolab Oy                |                 |                 |              |
| (Business ID 0427816-5)   |                 |                 |              |
--------------------------------------------------------------------------------
|   Series B shares         |          12,300 |            0.10 |         0.01 |
--------------------------------------------------------------------------------
| Total                     |          12,300 |            0.10 |         0.01 |
--------------------------------------------------------------------------------

Biohit Oyj's share capital consists of a total of 12,937,627 shares (2,975,500  
Series A shares and 9,962,127 Series B shares). Series A shares confer twenty   
(20) votes and Series B shares confer one (1) vote. In payment of dividends,    
however, a dividend of two (2) per cent higher than the nominal value is paid   
for Series B shares than is paid for Series A shares.                           


Biohit Oyj                                                                      
Osmo Suovaniemi                                                                 
President and CEO                                                               


Further information:                                                            

Osmo Suovaniemi, M.D., Ph.D., Professor                                         
President & CEO                                                                 
Tel: +358-9-773 861                                                             
GSM: +358-40-745 5605                                                           
Email: osmo.suovaniemi@biohit.com                                               

Distribution:                                                                   

Helsinki Exchanges                                                              
Central storage facility (www.oam.fi)                                           
Press                                                                           
www.biohit.com                                        

About Biohit Oyj                                                                

Biohit Oyj develops, manufactures and markets liquid handling products and      
diagnostic test systems for use in research, health care and industrial         
laboratories.                                                                   

Liquid handling products include electronic and mechanical pipettes and         
dispensers, and disposable tips, as well as pipette maintenance and calibration 
services. Diagnostics business comprises products and analysis systems for      
diagnosing, screening and prevention of gastrointestinal diseases, e.g. the     
blood-sample based GastroPanel and GastroView, for diagnosing diseases of the   
stomach and associated risks, as well as quick tests for the diagnosis of       
lactose intolerance, H. pylori infection and fecal occult blood.                

Biohit Group employs 370 people in 8 countries. Biohit Oyj is headquartered in  
Finland. Subsidiaries are located in France, Germany, the UK, Russia, China,    
Japan and the USA. Additionally, Biohit's products are sold by approximately 450
distributors in 70 countries. Biohit's share (BIOBV) is quoted on NASDAQ OMX    
Helsinki.                                                                       

Read more at www.biohit.com